MétaCan
Menu
← Back to cohort

The population-based impact of adjuvant chemotherapy (CTx) on outcomes in AJCC6 stage IB non-small cell lung cancer (NSCLC).

2018· article· en· W2891456907 on OpenAlexaffabout
Rahul K. Arora, Amanda Williams Gibson, D. Gwyn Bebb, Winson Y. Cheung

Bibliographic record

VenueJournal of Clinical Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Diagnosis and Treatment
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsMedicineInternal medicineOncologyCohortProportional hazards modelPopulationStage (stratigraphy)Logistic regressionLung cancerAdjuvantnon-small cell lung cancer (NSCLC)

Abstract

fetched live from OpenAlex

8523 Background: Adjuvant CTx is the standard of care in stage II and IIIA NSCLC, but its value in AJCC6 stage IB NSCLC (T2N0M0) is unclear. Guidelines suggest consideration of adjuvant CTx for stage IB patients at high recurrence risk, but CTx use is variable. Prior population-based studies lacked NSCLC-specific survival (CSS) and key covariates such as health insurance status. Using a Canadian cohort with universal health care coverage and CSS data, we aimed to identify predictors of use and assess the real-world benefit of adjuvant CTx in stage IB NSCLC. Methods: We examined all patients who underwent surgery for T2N0M0 NSCLC in a large Canadian province between 2004 and 2015 and categorized cases based on receipt of adjuvant CTx within 6 months of curative resection. We identified predictors of CTx receipt with logistic regression. We also identified correlates of overall survival (OS) and CSS using Kaplan-Meier methods and Cox regression. Results: 967 patients met eligibility criteria. Median age was 68 (IQR 61-74) years at diagnosis, 455 (47%) were men, and 164 (17%) received adjuvant CTx. Sex, topology, and laterality were similar in patients treated with or without CTx. Lower age at diagnosis, lower Charlson Comorbidity Index, large cell histology, and tumor size ≥ 4 cm were associated with higher likelihood of CTx receipt (all p < 0.05). In the entire cohort and in the subset with ≥ 4 cm tumors, CTx improved OS but not DSS on univariate analysis. In both groups, CTx did not correlate with OS or DSS on multivariate analysis (Table). Conclusions: Adjuvant CTx does not improve survival in this real-world cohort of T2N0M0 NSCLC patients, even for patients with ≥ 4cm tumors, suggesting that it has a limited role in real-world practice. Univariate and multivariate survival analysis for stage IB NSCLC patients based on receipt of CTx. All patients ≥ 4 cm tumors CTx No CTx P CTx No CTx p mOS (months) [95% CI] 104 [67-114] 78 [69-86] 0.058 111 [85-137] 71 [55-87] 0.030 mCSS (months) [95% CI] 135 [NR] NR 0.491 135 [NR] NR 0.827 Adjusted HR for OS [95% CI] 0.93 [0.69-1.24] 0.598 0.73 [0.45-1.16] 0.177 Adjusted HR for CSS [95% CI] 1.20 [0.84-1.70] 0.316 0.92 [0.53-1.58] 0.754 m = median; HR = hazard ratio; NR = not reached.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.004
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.591
Threshold uncertainty score0.823

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.004
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.002
Science and technology studies0.0010.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.062
GPT teacher head0.492
Teacher spread0.430 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2018
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicLung Cancer Diagnosis and Treatment→French-language works237,207→